Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

Journal of Experimental & Clinical Cancer Research : CR logoLink to Journal of Experimental & Clinical Cancer Research : CR
. 2020 Jan 16;39:14. doi: 10.1186/s13046-020-1526-z

Correction to: ZNF326 promotes malignant phenotype of glioma by up-regulating HDAC7 expression and activating Wnt pathway

Xinmiao Yu 1, Minghao Wang 2,, Jingjing Wu 3, Qiang Han 4, Xiupeng Zhang 4
PMCID: PMC6964022  PMID: 31941535

Correction to: J Exp Clin Cancer Res (2019) 38:40

https://doi.org/10.1186/s13046-019-1031-4

In the original publication of this manuscript [1], the author mislabeled the CTL group and ZNF326 group in Fig.2-I,J (MTT result). The revised Fig. 2 is shown below.

Fig. 2.

Fig. 2

Impact of ZNF326 expression on the proliferation and invasiveness of glioma cells in vitro. ZNF326 overexpression significantly enhanced the colony formation (a, b), invasiveness (e, f, magnification-400×), and proliferation (i, j) of U87 and U251 glioma cell lines. Conversely, ZNF326 knockdown significantly inhibited colony formation (c, d), invasiveness (g, h, magnification-400×), and proliferation (k, l) of U87 and U251 glioma cell lines. CTL: control group. Each experiment was performed in triplicate. Columns: mean numbers. Bars: S.D. (*: P < 0.05; **: P < 0.01; ***: P < 0.001)

The authors sincerely apologize for the inconvenience caused to the readers.

Reference

  • 1.Yu X, et al. ZNF326 promotes malignant phenotype of glioma by up-regulating HDAC7 expression and activating Wnt pathway. J Exp Clin Cancer Res. 2019;38:40. doi: 10.1186/s13046-019-1031-4. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Experimental & Clinical Cancer Research : CR are provided here courtesy of BMC

RESOURCES